Zu H, Gao D. Non-viral vectors in gene therapy: recent development, challenges, and prospects. AAPS J. 2021;23(4):78.
Butt MH, et al. Appraisal for the potential of viral and nonviral vectors in gene therapy: a review. Genes (Basel). 2022;13(8):1370.
Article CAS PubMed Google Scholar
Lee JH, Yeo Y. Controlled drug release from pharmaceutical nanocarriers. Chem Eng Sci. 2015;125:75–84.
Article CAS PubMed Google Scholar
Yao Y, et al. Nanoparticle-based drug delivery in cancer therapy and its role in overcoming drug resistance. Front Mol Biosci. 2020;7:193.
Article CAS PubMed PubMed Central Google Scholar
Swingle KL, et al. Amniotic fluid stabilized lipid nanoparticles for in utero intra-amniotic mRNA delivery. J Control Release. 2022;341:616–33.
Article CAS PubMed Google Scholar
Riley RS, et al. Ionizable lipid nanoparticles for in utero mRNA delivery. Sci Adv. 2021;7(3):eaba1028.
Article CAS PubMed PubMed Central Google Scholar
Bose SK, et al. In utero adenine base editing corrects multi-organ pathology in a lethal lysosomal storage disease. Nat Commun. 2021;12(1):4291.
Article CAS PubMed PubMed Central Google Scholar
Ricciardi AS, et al. In utero nanoparticle delivery for site-specific genome editing. Nat Commun. 2018;9(1):2481.
Article PubMed PubMed Central Google Scholar
• Deprest JA, et al. Randomized trial of fetal surgery for severe left diaphragmatic hernia. N Engl J Med. 2021;385(2):107–18. Findings from this important randomized clinical trial provided evidence that the use of FETO for CDH resulted in significant benefit over observation or expectant management alone.
Article PubMed PubMed Central Google Scholar
Montalva L, et al. Neurodevelopmental impairment in children with congenital diaphragmatic hernia: not an uncommon complication for survivors. J Pediatr Surg. 2020;55(4):625–34.
Montalva L, Zani A. Assessment of the nitrofen model of congenital diaphragmatic hernia and of the dysregulated factors involved in pulmonary hypoplasia. Pediatr Surg Int. 2019;35(1):41–61.
Greer JJ. Current concepts on the pathogenesis and etiology of congenital diaphragmatic hernia. Respir Physiol Neurobiol. 2013;189(2):232–40.
Goncalves AN, Correia-Pinto J, Nogueira-Silva C. ROBO2 signaling in lung development regulates SOX2/SOX9 balance, branching morphogenesis and is dysregulated in nitrofen-induced congenital diaphragmatic hernia. Respir Res. 2020;21(1):302.
Article CAS PubMed PubMed Central Google Scholar
Mous DS, et al. Pulmonary vascular development in congenital diaphragmatic hernia. Eur Respir Rev. 2018;27(147).
Wynn J, Yu L, Chung WK. Genetic causes of congenital diaphragmatic hernia. Semin Fetal Neonatal Med. 2014;19(6):324–30.
Article PubMed PubMed Central Google Scholar
Cushing L, et al. The roles of microRNAs and protein components of the microRNA pathway in lung development and diseases. Am J Respir Cell Mol Biol. 2015;52(4):397–408.
Article CAS PubMed PubMed Central Google Scholar
Pereira-Terra P, et al. Unique tracheal fluid microRNA signature predicts response to FETO in patients with congenital diaphragmatic hernia. Ann Surg. 2015;262(6):1130–40.
Chan YC. MicroRNA regulation of angiogenesis. In: Sen CK, editor. MicroRNA in regenerative medicine. Academic Press; 2023. p. 539–72.
• Ullrich SJ, et al. In utero delivery of miRNA induces epigenetic alterations and corrects pulmonary pathology in congenital diaphragmatic hernia. Mol Ther Nucleic Acids. 2023;32:594–602. This study shows promise that the delivery of particle therapy carrying miRNA200b reverses the CDH phenotype and is a potentially translatable treatment.
Article CAS PubMed PubMed Central Google Scholar
Mandl HK, et al. Optimizing biodegradable nanoparticle size for tissue-specific delivery. J Control Release. 2019;314:92–101.
Article CAS PubMed PubMed Central Google Scholar
Kauffman AC, et al. Tunability of biodegradable poly(amine- co-ester) polymers for customized nucleic acid delivery and other biomedical applications. Biomacromolecules. 2018;19(9):3861–73.
Article CAS PubMed PubMed Central Google Scholar
Ambegia E, et al. Stabilized plasmid-lipid particles containing PEG-diacylglycerols exhibit extended circulation lifetimes and tumor selective gene expression. Biochim Biophys Acta. 2005;1669(2):155–63.
Article CAS PubMed Google Scholar
Gao Y, et al. Multifunctional nanoparticle for cancer therapy. MedComm (2020). 2023;4(1):e187.
• Luks VL, et al. Surface conjugation of antibodies improves nanoparticle uptake in bronchial epithelial cells. PLoS One. 2022;17(4):e0266218. This study highlights how particles can be edited to make them tissue and cell specific.
Article CAS PubMed PubMed Central Google Scholar
Ullrich SJ, et al. Nanoparticles for delivery of agents to fetal lungs. Acta Biomater. 2021;123:346–53.
Article CAS PubMed PubMed Central Google Scholar
Khoshgoo N, et al. MicroRNA-200b regulates distal airway development by maintaining epithelial integrity. Sci Rep. 2017;7(1):6382.
Article PubMed PubMed Central Google Scholar
Manning SM, Jennings R, Madsen JR. Pathophysiology, prevention, and potential treatment of neural tube defects. Ment Retard Dev Disabil Res Rev. 2000;6(1):6–14.
Article CAS PubMed Google Scholar
Davis BE, et al. Long-term survival of individuals with myelomeningocele. Pediatr Neurosurg. 2005;41(4):186–91.
Farrelly JS, et al. Alginate microparticles loaded with basic fibroblast growth factor induce tissue coverage in a rat model of myelomeningocele. J Pediatr Surg. 2019;54(1):80–5.
Adzick NS, et al. A randomized trial of prenatal versus postnatal repair of myelomeningocele. N Engl J Med. 2011;364(11):993–1004.
Article CAS PubMed PubMed Central Google Scholar
Espinoza J, et al. Two-port, exteriorized uterus, fetoscopic meningomyelocele closure has fewer adverse neonatal outcomes than open hysterotomy closure. Am J Obstet Gynecol. 2021;225(3):327e1–9.
Keil C, et al. Implementation and assessment of a laparotomy-assisted three-port fetoscopic spina bifida repair program. J Clin Med. 2023;12(15):5151.
Article PubMed PubMed Central Google Scholar
Sanz Cortes M, et al. Ambulation after in-utero fetoscopic and open spina bifida repair: predictors for ambulation at 30 months. Ultrasound Obstet Gynecol. 2024. https://doi.org/10.1002/uog.27589. Epub ahead of print. PMID: 38243917.
Watanabe M, Kim AG, Flake AW. Tissue engineering strategies for fetal myelomeningocele repair in animal models. Fetal Diagn Ther. 2015;37(3):197–205.
Dionigi B, et al. Trans-amniotic stem cell therapy (TRASCET) minimizes Chiari-II malformation in experimental spina bifida. J Pediatr Surg. 2015;50(6):1037–41.
Shieh HF, et al. Transamniotic stem cell therapy (TRASCET) in a rabbit model of spina bifida. J Pediatr Surg. 2019;54(2):293–6.
Turner CG, et al. Intra-amniotic delivery of amniotic-derived neural stem cells in a syngeneic model of spina bifida. Fetal Diagn Ther. 2013;34(1):38–43.
Chen YJ, et al. Fetal surgical repair with placenta-derived mesenchymal stromal cell engineered patch in a rodent model of myelomeningocele. J Pediatr Surg. 2017. https://doi.org/10.1016/j.jpedsurg.2017.10.040. Epub ahead of print. PMID: 29096888.
Article PubMed PubMed Central Google Scholar
Galganski LA, et al. In utero treatment of myelomeningocele with placental mesenchymal stromal cells - selection of an optimal cell line in preparation for clinical trials. J Pediatr Surg. 2020;55(9):1941–6.
Stokes SC, et al. Impact of gestational age on neuroprotective function of placenta-derived mesenchymal stromal cells. J Surg Res. 2022;273:201–10.
留言 (0)